Axitinib (CAS 319460-85-0)

Application and positioning

Axitinib is a selective inhibitor of vascular endothelial growth factor receptors VEGFR-1, -2 and -3, which limits tumour angiogenesis. It is formulated into oral tablets for advanced renal cell carcinoma, frequently in combination with immune checkpoint inhibitors. Laurand supplies it from audited Chinese production partners for pharmaceutical manufacturing and process development.

Quality and documentation

• Batch-specific Certificate of Analysis issued by the manufacturing site
• SDS/MSDS and specification sheet available on request
• Residual solvents and elemental impurities statements discussed per project
• For pharmaceutical manufacturing and R&D use only — not for direct administration

Packaging and handling

• Packed in double polyethylene-lined fibre drums; pack size confirmed at quotation
• Small quantities in sealed aluminium foil bags
• Palletised for air and sea freight; store dry, ventilated and protected from light

Related products

• Crizotinib (CAS 877399-52-5)
• Dacomitinib (CAS 1110813-31-4)
• Galunisertib (CAS 700874-72-2)
• Ibrutinib (CAS 936563-96-1)
• (E)-6-Nitro-3-[2-(pyridin-2-yl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (CAS 886230-75-7)
• 6-Iodo-1H-indazole (CAS 261953-36-0)

Specifications shown are indicative. The final specification and documentation package are confirmed with the quotation.